Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $120
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $123 to $120.
Share
Why It Matters
A money expert still likes Spyre but thinks it might be worth slightly less money. This shows the company is still doing okay, even if the expert is a tiny bit less excited.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.